These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9484362)

  • 1. Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing remitting multiple sclerosis.
    Gasperini C; Pozzilli C; Bastianello S; Koudriavtseva T; Galgani S; Millefiorini E; Paolillo A; Horsfield MA; Bozzao L; Fieschi C
    Neurology; 1998 Feb; 50(2):403-6. PubMed ID: 9484362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.
    Pozzilli C; Bastianello S; Koudriavtseva T; Gasperini C; Bozzao A; Millefiorini E; Galgani S; Buttinelli C; Perciaccante G; Piazza G; Bozzao L; Fieschi C
    J Neurol Neurosurg Psychiatry; 1996 Sep; 61(3):251-8. PubMed ID: 8795595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis.
    Richert ND; Ostuni JL; Bash CN; Leist TP; McFarland HF; Frank JA
    Mult Scler; 2001 Feb; 7(1):49-58. PubMed ID: 11321194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-beta-1a in relapsing-remitting multiple sclerosis: effect on hypointense lesion volume on T1 weighted images.
    Gasperini C; Pozzilli C; Bastianello S; Giugni E; Horsfield MA; Koudriavtseva T; Galgani S; Paolillo A; Haggiag S; Millefiorini E; Fieschi C
    J Neurol Neurosurg Psychiatry; 1999 Nov; 67(5):579-84. PubMed ID: 10519861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
    Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
    Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b.
    Rao AB; Richert N; Howard T; Lewis BK; Bash CN; McFarland HF; Frank JA
    Neurology; 2002 Sep; 59(5):688-94. PubMed ID: 12221158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum soluble intercellular adhesion molecule-I in MS: relation to clinical and Gd-MRI activity and to rIFN beta-Ib treatment.
    Trojano M; Avolio C; Ruggieri M; Defazio G; Giuliani F; Paolicelli D; Livrea P
    Mult Scler; 1998 Jun; 4(3):183-7. PubMed ID: 9762671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of clinical relapses and steroid therapy on the development of Gd-enhancing lesions: a longitudinal MRI study in relapsing-remitting multiple sclerosis patients.
    Gasperini C; Pozzilli C; Bastianello S; Koudriavtseva T; Colleluori A; Millefiorini E; Thompson AJ; Horsfield MA; Galgani S; Bozzao L; Fieschi C
    Acta Neurol Scand; 1997 Apr; 95(4):201-7. PubMed ID: 9150809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon beta treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology.
    Filippi M; Rovaris M; Capra R; Gasperini C; Prandini F; Martinelli V; Horsfield MA; Bastianello S; Sormani MP; Pozzilli C; Comi G
    J Neurol Neurosurg Psychiatry; 1999 Sep; 67(3):386-9. PubMed ID: 10449565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of weekly intramuscular interferon beta-1a on MRI lesions in patients with relapsing multiple sclerosis].
    Waubant E; Sloan R; Andersson PB; Goodkin D
    Rev Neurol (Paris); 1999; 155 Suppl 2():S20-3. PubMed ID: 10367321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
    Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cumulative effect of a weekly low dose of interferon beta 1a on standard and triple dose contrast-enhanced MRI from multiple sclerosis patients.
    Rovaris M; Capra R; Martinelli V; Gasperini C; Prandini F; Pozzilli C; Comi G; Filippi M
    J Neurol Sci; 1999 Dec; 171(2):130-4. PubMed ID: 10581379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment.
    Avolio C; Filippi M; Tortorella C; Rocca MA; Ruggieri M; Agosta F; Tomassini V; Pozzilli C; Stecchi S; Giaquinto P; Livrea P; Trojano M
    Mult Scler; 2005 Aug; 11(4):441-6. PubMed ID: 16042227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis.
    Miller DH; Molyneux PD; Barker GJ; MacManus DG; Moseley IF; Wagner K
    Ann Neurol; 1999 Dec; 46(6):850-9. PubMed ID: 10589537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
    Cohen JA; Imrey PB; Calabresi PA; Edwards KR; Eickenhorst T; Felton WL; Fisher E; Fox RJ; Goodman AD; Hara-Cleaver C; Hutton GJ; Mandell BF; Scott TF; Zhang H; Apperson-Hansen C; Beck GJ; Houghtaling PL; Karafa MT; Stadtler M;
    Neurology; 2009 Feb; 72(6):535-41. PubMed ID: 19204263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newer versus older treatments for relapsing-remitting multiple sclerosis.
    Weinstock-Guttman B; Cohen JA
    Drug Saf; 1996 Feb; 14(2):121-30. PubMed ID: 8852526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.
    Arnold DL; Calabresi PA; Kieseier BC; Liu S; You X; Fiore D; Hung S
    BMC Neurol; 2017 Feb; 17(1):29. PubMed ID: 28183276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure.
    Stone LA; Frank JA; Albert PS; Bash CN; Calabresi PA; Maloni H; McFarland HF
    Neurology; 1997 Sep; 49(3):862-9. PubMed ID: 9305355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic resonance imaging outcome of new enhancing lesions in relapsing-remitting multiple sclerosis patients treated with interferon beta1a.
    Paolillo A; Bastianello S; Frontoni M; Gasperini C; Giugni E; Ciccarelli O; Luccichenti G; Cannoni S; Pozzilli C
    J Neurol; 1999 Jun; 246(6):443-8. PubMed ID: 10431768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
    Lancet; 1998 Nov; 352(9139):1498-504. PubMed ID: 9820297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.